Last year I wrote about the results of the OCEANS Study ( phase III trial of gemcitabine, carboplatin and bevacizumab or gemcitabine, carboplatin and placebo) . This year Dr. Aghajanian presented the safety analysis data from the OCEANS .
An updated safety analysis of OCEANS, a randomized, double-blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer.
"Conclusions: The overall safety profile was similar to that seen at the time of the final PFS( progression free survival) analysis. Higher incidences of proteinuria ( excess protein in urine) and HTN ( Hypertension)were possibly related to longer BV treatment duration and resolved in the majority of patients."
Every Day is a Blessing